New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Monte Rosa Therapeutics, Inc.
GLUE
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

582M

Biotechnology

Next Earning date - 14 Nov 2024

582M

Biotechnology

Next Earning date - 14 Nov 2024

9.48USD
Shape4.59 ( 93.86%)
favorite-chart

Relative Strenght

10
favorite-chart

Volume Buzz

27051%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

24%

Quote Panel

Shape
Updated October 28, 2024
1W 78.53 % 1M 78.87 % 3M 107.44 % 1Y 205.81 %

Key Metrics

Shape
  • Market Cap

    581.81M


  • Shares Outstanding

    61.37M


  • Share in Float

    44.59M


  • Dividende

    0


  • Earning Date

    14 Nov 2024


  • Price Target

    9.48


  • Average Volume

    349351


  • Beta

    1.424


  • Range

    2.765-12.4


  • Industry

    Biotechnology


  • Website

    https://www.monterosatx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

40.09x

P/S Ratio

3.01x

P/B Ratio

0.2

Debt/Equity

-898.7%

Net Margin

$-2.2

EPS

How GLUE compares to sector?

P/E Ratio

Relative Strength

Shape

GLUE

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$11M

Shape132%

2025-Revenue

$1.93

Shape-348%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wedbush

initialise

Previous: Not converted

2024-02-15

Now: Outperform

Wells Fargo

upgrade

Previous: Not converted

2023-01-03

Now: Overweight

Credit Suisse

initialise

Previous: Not converted

2022-04-28

Now: Neutral

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.58
vs -0.43

Q4.22

arrow
arrow

N/A

-0.63
vs -0.51

Q1.23

arrow
arrow

N/A

-0.65
vs -0.51

Q2.23

arrow
arrow

N/A

-0.71
vs -0.57

Q3.23

arrow
arrow

N/A

-0.70
vs -0.58

Q4.23

arrow
arrow

N/A

-0.58
vs -0.63

Q1.24

arrow
arrow

N/A

-0.53
vs -0.65

Q2.24

arrow
arrow

N/A

-0.43
vs -0.71

Q3.24

arrow
arrow

N/A

-0.47
vs -0.70

Q4.24

arrow
arrow

N/A

-0.48
vs -0.58

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

8.8M  vs NA

Q1.24

arrow
arrow

NA

1.1M  vs NA

Q2.24

arrow
arrow

NA

4.7M  vs NA

Q3.24

arrow
arrow

NA

2.6M  vs NA

Q4.24

arrow
arrow

-65%

3M  vs 8.8M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-9%

-0.09
vs -0.09

Q4.22

arrow
arrow

-11%

-0.11
vs -0.09

Q1.23

arrow
arrow

-12%

-0.12
vs -0.11

Q2.23

arrow
arrow

-16%

-0.16
vs -0.12

Q3.23

arrow
arrow

-19%

-0.19
vs -0.16

Q4.23

arrow
arrow

-19%

-0.19
vs -0.19

Q1.24

arrow
arrow

-21%

-0.21
vs -0.19

Q2.24

arrow
arrow

-13%

-0.13
vs -0.21

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

70

70
vs 57

23%

Q4.22

arrow
arrow

69

69
vs 70

-1%

Q1.23

arrow
arrow

71

71
vs 69

3%

Q2.23

arrow
arrow

70

70
vs 71

-1%

Q3.23

arrow
arrow

75

75
vs 70

7%

Q4.23

arrow
arrow

79

79
vs 75

5%

Q1.24

arrow
arrow

71

71
vs 79

-10%

Q2.24

arrow
arrow

76

76
vs 71

7%

Earnings Growth

Latest News